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ABSTRACT

A COMPARATIVE ANALYSIS OF HYDROLYSIS KINETICS BY sPLA2
ISOFORMS DURING APOPTOSIS IN S49 CELLS

Erin D. Olson
Department of Physiology & Developmental Biology
Master of Science

Secretory Phospholipase A2 (sPLA2) represents a diverse class of roughly
20 enzymes, 12 of which have been identified in humans. These isoforms can
be distinguished based on their tissue distribution, structure, and regulation.
These differences in structure between the isoforms lead to the question does
the enzyme’s ability to respond to physical changes in the membrane during
apoptosis governed by structure. S49 cell apoptosis was initiated by treatment
with either the glucocorticoid dexamethasone (6–48 h) or with the calcium

ionophore, ionomycin. The rates of hydrolysis were compared with each
treatment condition for various concentrations of snake venom
and human groups (hG) IIA, V, and X isoforms. The data were analyzed using a
model that explicitly evaluates both the adsorption of enzyme to the membrane
surface (step 1) and subsequent binding of substrate to the active site (step 2).
Increased hydrolysis during apoptosis appeared to reflect step 2 for both the
snake venom and the hGX enzymes. In contrast, apoptosis promoted step 1 for
hGV. For hGIIA, the kinetics were more complex suggesting additional
mechanisms beyond these two steps. These observations are rationalized in
terms of the structure of the various isozymes and physical changes during
apoptosis, including reduction in the strength of lipid/neighbor interactions and
increased bilayer surface charge.
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INTRODUCTION
There are two classical pathways in the cell death spectrum that are categorized
as the extremes; apoptosis and necrosis. Necrosis is generally characterized by
cells that have irreversible swelling of the cytoplasm and distortion of organelles.
This mode of cell death usually occurs when cells have been exposed to
hyperthermia, metabolic poisons and other direct traumas (1). Cells that undergo
apoptosis can be biologically distinguished by their physical characteristics that
include condensation of the cytoplasmic and nuclear membranes, microvesicle
shedding, and blebbling of the plasma membrane. Biochemically, apoptosis is
marked by DNA fragmentation, activation of aspartate-specific proteases known
as caspases, and the exposure of phosphatidylserine (PS) on the outer leaflet of
the membrane (2). Even though caspase activation is not necessary for
apoptosis to occur, the morphological changes that characterize apoptosis are
the direct result of caspase activation and cleavage (3, 4). Aside from the
physical aspects, apoptosis also differs from necrosis by its functional role in
development. The apoptosis pathway plays an integral role in cell proliferation,
differentiation, activation, and removal during development. Because apoptosis
is such an important component in the many stages of development, it can be
considered as one of the fundamental aspects of cellular life (1, 2).
Within apoptosis, there are three phases; the initiation phase, the effector
phase and the degradation phase. The initiation phase consists of cells receiving
death-inducing signals that include the binding of certain ligands to deathtransmitting receptors, and withholding of obligatory survival factors and
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metabolite supply. After these signals are received, the effector phase is initiated
and translates these signals into metabolic pathways, where the decision is
finalized and the degradation phase is commenced (1).
Apoptosis occurs through either of two main (classical) pathways: the
intrinsic pathway, which is a mitochondrial-dependent pathway, and the
extrinsic/receptor-mediated pathway (2). The extrinsic pathway plays an integral
role in inflammation and homeostasis of the tissue and can be activated through
a variation of signaling cascades. Examples of these cascades include activation
of a tumor necrosis factor family member, the Fas-Fas death receptor, or the
localized secretion of lytic granules containing perforin on granzymes (2). An
example of an apoptosis inducer that would use this pathway would be the
ionophore, ionomycin (2, 5).
The intrinsic pathway is regulated by external cues and internal insults,
such as proteins with death domains and DNA damage. In response to apoptotic
stimuli given by the death domains, the outer mitochondrial membrane becomes
permeable and releases cytochrome-c into the cytosol. Once released,
cytochrome-c, interacts with Apoptotic protease-activating factor-1 (Apaf-1) which
then activates a cascade of caspase proenzymes leading to apoptosis. An
important regulator of this pathway, which contains both pro and anti-apoptotic
members, is the Bcl-2 protein family (2). Both classical pathways then converge
into a single pathway involving the activation of caspases that ultimately cleave
regulatory and structural molecules, resulting in cell death.
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However, recent studies have shown that there are exceptions employing
a different route besides these two classical pathways. One exception is
dexamethasone, a hormone that is part of a class of steroids called
glucocorticoids (GC) (6). Instead of acting upon a death receptor or using
mitochondrial response, these hormones bind to an intracellular glucocorticoid
receptor (GR). After GC’s pass through the membrane and dock onto the GR,
the GR is released from its complex of heat shock proteins allowing it to pass
through into the nucleus and bind to DNA or other transcription factors. Herald et
al. state that even though GC-induced apoptosis does not proceed through one
of the classic pathways, many genes or proteins such as caspases and Bcl-2 are
activated and play crucial roles in this signaling cascade (6). Other examples of
non-classical pathways include the Fas-ligand pathways used by cytotoxic T
cells, or the perforin/granzyme B-dependent pathway used by natural killer cells
(2).
Another event appearing to correspond with apoptosis, is the susceptibility
of cells normally resistant to the enzyme secretory phospholipase A2 (sPLA2) (5,
7, 8). In addition to the ability of sPLA2 to hydrolyze the sn-2 fatty acyl bond of
membrane phospholipids, the enzyme is also able to differentiate between
healthy and dying cells. This has been shown with the membranes of
erythrocytes and S49 lymphoma cells (9, 10). However, the mechanism by
which sPLA2 distinguishes between healthy and apoptotic cells, after initial
adsorption, is not yet known, but appears to involve changes in membrane
physical properties (5). Nevertheless, these experiments have relied mostly on
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sPLA2 enzymes purified from various snake venoms, and not from enzymes
found naturally within the human body. The relationship between apoptosis and
susceptibility to human group isoforms has not yet been established.
Previously, a relationship has been shown between the structure of the
various isoforms of sPLA2 and their propensity for hydrolyzing artificial
membranes possessing specific physical and chemical properties (11). One
specific way in which these enzymes differ is their requirement for a negatively
charged membrane to facilitate enzyme adsorption to the bilayer surface. For
the hG-IIA enzyme, it is thought that a negative charge around the membrane is
necessary for adsorption. In contrast, for the snake venom, hG-X, and the hG-V
enzyme it is thought that a negatively charged membrane only enhances
adsorption. Numerous studies have also demonstrated that membrane
hydrolysis involves two steps (Scheme 1) (11, 12). The first step consists of
enzyme adsorption to the phospholipid membrane, and the second step involves
movement of the phospholipid head into the active site of the enzyme.
Based on these findings, we hypothesize that it is possible to say that the
hG enzymes will behave the same when hydrolyzing nucleated cells as when
they are interacting with artificial membranes. We also predict that (1) the afore
mentioned model (Scheme 1) should hold true for the sPLA2 isoforms, and (2)
the differences between these isoforms would be in terms of the kinetic
parameters, KA and KE, rather then in differences in the fundamental mechanics.
These quantitative differences will distinguish the different isoforms of sPLA2.
However, the limiting step will continue to be the ability of the phospholipid to
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access the active site of bound sPLA2,and that this step will universally be a
property of the membrane rather than of the enzyme. This hypothesis was
tested by assessing the kinetics of membrane hydrolysis by four isoforms of
sPLA2 at various times during apoptosis and then comparing the results to
enzyme structure and/or function. The sPLA2 isoforms that were chosen were
three recombinant human forms: (hG)—hG-IIA, hG-V, hG-X and snake venom
from Agkistrodon piscivorus piscivorus. These variants were chosen because
they have been well characterized structurally and enzymatically, and because
they appear to have distinct functions within the human body. Human group IIA is
synthesized in platelets and found in tears, and synovial fluid (13). Human group
V is found primarily within the heart and is thought to be the evolutionary
duplicate of the hG-IIA enzyme (14). Human group X is found mostly in immune
tissues (13). Even though many questions have been answered about
differences among these isoforms, results in current research are not yet
sufficient to adequately compare hydrolysis kinetics in nucleated cells (14, 15).
The purpose of this study was to understand how apoptosis, induced by
either a calcium ionophore or glucocorticoid, might increase the rate of
phospholipid hydrolysis by extracellular sPLA2. The basis for choosing
ionomycin and dexamethasone as apoptotic reagents were for their similarities to
natural causes of cell death. Ionomycin causes cell death by raising intracellular
calcium to a high sustained level reminiscent of traumatic injury, or necrosis. In
contrast, dexamethasone treatment emulates stress induced cortisol release
and therefore emulates physiological induction of apoptosis. By further
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understanding hydrolysis for both ends of the cell death spectrum (necrosis and
apoptosis), we will be able to better characterize hydrolysis factors of the sPLA2
enzyme and its isoforms.
Experiments for this study were designed to examine each of the
parameters shown in Scheme 1 and to assess which step(s) is/are involved in
distinguishing resistant cells from those treated with either ionomcyin or
dexamethasone. The results demonstrate that among the different isoforms,
modulation of either step one or step two (Scheme 1) may account for the
increased susceptibility to sPLA2, depending upon the isoform. In order to better
visualize how Scheme 1 will be used to assess the limiting step for each isoform
during hydrolysis, hypothetical graphs were created (Fig. 1). These graphs will
be used as a standard in determining the limiting step.

MATERIALS AND METHODS
Reagents
The monomeric aspartate-49 phospholipase A2 from the venom of A. p.
piscivorus was isolated according to the procedure of Maraganore et al. (16).
Recombinant hG-IIA and -X were provided by Michael Gelb and prepared using
the procedures outlined in Baker and Markova et.al. respectively (14, 17).
Human group V was provided by Wonwha Cho and was prepared according to
Cho et al. (18). Ionomycin was purchased from Calbiochem (La Jolla, CA) and
dissolved in dimethylsulfoxide (DMSO) for these experiments. Acrylodan-labeled
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fatty acid-binding protein (ADIFAB), propidium iodide, cell culture medium, and
serum were acquired from Invitrogen (Carlsbad, CA). Other reagents were
obtained from standard sources. Probes were dissolved in various solvents as
follows: ADIFAB in 50 mM KCl and 3 mM NaN3, and propidium iodide in distilled
water.

Cell Culture and Experimental Protocol
S49 mouse lymphoma cells were grown at 37 °C in humidified air, containing
10% CO2, and prepared for experiments as described in Wilson et al. (19). Cell
viability averaged 93 ± 3% (standard deviation) for control experiments, and
ranged between 5 – 96% for treatment experiments. For spectral and kinetic
experiments, an aliquot of cells (usually between 0.4–3.5 x 106 cells/ml in MBSS)
was then transferred to a quartz fluorometer sample cell and allowed 5 min to
equilibrate in the spectrofluorometer (Fluoromax 3, Horiba Jobin-Yvon, Edison,
NJ). Spectral bandpass for experiments in the fluorometer were set at 4 nm.
Data acquisition over time at multiple wavelengths (ADIFAB, propidium iodide)
was accomplished by rapid sluing of fluorometer mirrors under the control of
instrument software. Temperature and sample homogeneity were maintained as
described previously in Harris et al. (20). All experiments and incubations were
performed at 37 °C.

Membrane Hydrolysis
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Ionomycin: The fluorescent fatty acid binding protein ADIFAB (excitation, 390
nm; emission, 432 nm and 505 nm) was used to assay the release of fatty acids
from cell membranes in real time. After initiating data acquisition for 100 s,
ADIFAB (65 nM final) and ionomycin (300 nM final) were added. At 700 s, a
sPLA2 isoform (0.7 – 70 nM final) was added and the time course continued for
an additional 800-2000 s. Raw data were quantified by calculating the
generalized polarization (GP) from the 432 and 505 intensities, and fitted to an
arbitrary function by nonlinear regression (20).
Propidium iodide (PI) (37 µM final) (excitations at 537 and emission at 617)
was used to assess how many cells had become permeable to the probe due to
perturbations caused by hydrolysis as described in (19). Experimental protocol
for PI was similar to that of ADIFAB, differing only in probe usage. Previous
studies have demonstrated that assays with ADIFAB and propidium iodide
provide identical results under conditions at which cells are susceptible to the
enzyme’s catalytic activity (19).

Dexamethasone: Experiments where cells that were treated with the
glucocoritcoid, dexamethasone (100 nM final), for various lengths of time (6-48
hrs), or with varying concentrations at 24 h were the same. Hydrolysis and cell
susceptibility were measured with ADIFAB and PI, respectively. After initiating
data acquisition for 100 s, ADIFAB (65 nM final) and PI (37 µM final) were added.
At 400 s, various isoforms (hG- IIA, -V, -X, and snake venom) of sPLA2 (35 nM
final for experiments were incubation length was varied, and 0.7 – 70 nM final for
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experiments where enzyme concentrations was varied). At 1000 s ionomycin
(300 nM final) was added and the time course continued for an additional 600–
1000 s.

Propidium Iodide: Intensity of PI fluorescence was used to quantify cell
susceptibility to the sPLA2 enzyme, after control solvent (DMSO) or treatment
(dexamethasone followed by ionomycin) was added to the samples. Data points
between the time of PI addition and ionomycin addition were fit to an arbitrary
function by nonlinear regression, and then were used to quantify the cells into
different populations. These populations were then named for their distinct
characteristics. Cells that took up PI immediately after addition of the probe were
classified as “dead”; cells that took up PI only after addition of the enzyme
isoform were classified as “alive but susceptible”; and cells that were only
susceptible to the enzyme isoform after ionomycin addition were classified as
“alive but resistant”. Data from the maximum fluorescence signal after ionomycin
addition in control samples for each set of experiments were used as a standard
to assess total cell hydrolysis. However, occasionally, the snake venom
experimental sample was used as the standard when the control sample was
unusable due to experimental complications. This standard was used to account
for the cellular DNA that was completely fragmented during the experiment and
was invisible to the probe. To account for variations of cell number, data were
normalized to cell count (by hemocytometer and light microscopy) and light
scatter values separately. For most experiments, an average of both light scatter
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and cell count were used to improve accuracy. However, in some cases, only
light scatter was used, due to erroneous cell counts.

Data Analysis: Data plotting, statistical tests and linear and nonlinear regression
analyses were performed with Prism Graphpad software.

RESULTS
Ionomycin treatment was used to answer the following questions. First, what is
the hydrolysis potency of each of the enzyme isoforms? Second, how do the
human group isoform potencies compare to that of the snake venom isoform?
Third, are the potencies for each of the isoforms significantly enhanced when
treated with ionomycin compared to those of the control? Ionomcyin treatment
was also used as a preliminary determinant for concluding which step in Scheme
1 is limiting for each of the isoforms.

Ionomcyin
Snake venom: Addition of sPLA2 to S49 cells previously exposed (10 min) to a
control vehicle (DMSO) caused a slight increase in ADIFAB GP followed by a
gradual decline, nearly restoring the value to its original level (Fig. 2 curve b).
Other studies show this unusual hydrolysis time course represents transient
initial hydrolysis, followed by re-acylation of the lipids and reincorporation into the
membrane. In contrast, prior exposure of cells to ionomycin resulted in a large
10

increase in ADIFAB GP that quickly reached a stable plateau (Fig. 2 curve a).
ADIFAB is an acrylodan labled intestinal fatty acid binding protein. In the
absence of fatty acid, the acrylodan fluorophore in ADIFAB occupies the free
fatty acid binding site and fluoresces at 432 nm. In the presence of free floating
fatty acids, the acrylodan fluorophore is displaced and exposed to the solvent
and thus fluoresces at 505 nm. The sensitivity of acrylodan to the solvent
relaxation effect results in a decrease of intensity at 432 nm that is directly
proportional to the increase of intensity at 505 nm. This change in intensity is
used to determine how much hydrolysis occurs during experiments.
In order to further characterize hydrolysis kinetics, the experiment
represented in Figure 2 was repeated multiple times at various enzyme
concentrations. Data were analyzed by nonlinear regression (examples are
shown in Fig. 2). From these phenomenological fits, two parameters were
determined: the initial rate of hydrolysis, and the maximum hydrolysis product
generated. As displayed in Figure 3, treatment of cells with ionomycin increased
both initial and total hydrolysis at all enzyme concentrations. The maximum
hydrolysis rate was 0.018 ± 0.004 GP units s-1 for DMSO-treated samples and
0.093 ± 0.011 GP units s-1 for the ionomycin group. The enzyme concentration
at which the hydrolysis rate was one-half the maximum, measured 13.5 ± 7.8 nM
and 9.4 ± 3.2 nM for the two groups, respectively. Two-way analysis of variance
indicated that both the effects of enzyme concentration and ionomycin treatment
on the initial hydrolysis rate were highly significant (p < 0.0001). A significant
interaction (p < 0.0001) between the two variables was also observed,
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suggesting that the magnitude of the effect of ionomycin depended on enzyme
concentration. The ability of ionomycin treatment to increase total hydrolysis
product was also significant (p < 0.0001).
In addition to calculating the kinetic parameters in Figure 3 (Vmax and EC50
values), we also compared the curves in Figure 3 to the hypothetical curves in
Figure 1. This comparison illustrated the similarity between the snake venom
isoform data in Figure 3, and the hypothetical curve for Scheme 1 where the
limiting step is step two. These results suggest that the limiting step for the
snake venom isoform is step two.

Human group isoforms: S49 cells that were treated with the control vehicle
(DMSO) showed no significant changes in ADIFAB GP upon addition of the hGIIA and –V isoforms. Control experiments where cells were treated hG-X
displayed a marginal increase of ADIFAB GP, followed by a gradual decline
nearing the original values (Fig. 4: Panel D). The hG-X results were very similar
to that of the snake venom ionomycin experiments, and it is thought that the
same phenomenon of re-acylation is occurring. Exposure of the cells to
ionomycin, showed an increase of both hydrolysis rate and amount for the hG-V
and –X isoforms, and showed no effect on the rate or amount of hydrolysis for
the hG-IIA isoform. Although, the extent of these increases depended upon the
isoform and was always less than that observed with the snake venom enzyme
Of the three human group isoforms, hG-X was the most active upon cells
treated with the calcium ionophore. Similar to that of the snake venom, the hG-X
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isoform showed a large initial increase of hydrolysis that quickly reached a
plateau (Fig. 4: Panel D). The hG-V isoform was the second most active, but
enzyme activity was modest when compared to that of the hG-X or snake venom
enzyme. Unlike that of the snake venom or the hG-X isoforms, hydrolysis by the
hG-V isoform was gradual and never reached a plateau (Fig. 4: Panel C).
Human group IIA hydrolyzed very little or no phospholipids from calcium
ionophore-treated cells and showed no significant difference in ADIFAB GP
between the control and treatment experiments (Fig. 4: Panel B).
Like in the snake venom section, we further characterized the hydrolysis
kinetics of each sPLA2 isoforms by calculating the initial rates. This was done by
repeating the experiments of Figure 4 with varying concentrations of each
isoform. The data were then analyzed using nonlinear regression (Fig. 5). As
shown in Figure 5, there was an increase in initial hydrolysis rates for all isoforms
except for hG-IIA (Fig. 5: Panel B), for which there was no consistent difference
between ionomycin- and DMSO-treated samples. The maximum hydrolysis rates
for each of the isoforms were calculated and are shown in Table 2. However,
unlike the snake venom enzyme, there was no significant interaction between the
two variables for the human group isoforms. We therefore conclude that
ionomycin enhances hydrolysis for hG-V and –X isoforms, but not for the hG-IIA
(Fig. 5).
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Dexamethasone
The experiments with ionomycin were now expanded to include dexamethasone
as the inducer of cell death. This was done for two reasons. First, we
investigated how sPLA2 isoforms differed in their hydrolysis abilities from one
another in a physiological apoptotic setting. Second, we compared how
hydrolysis differs in an apoptotic setting from that of a necrotic (ionomycin)
setting.
Dexamethasone experiments were divided into two types of experiments;
(1) experiments where incubation length varied while enzyme concentrations
were held constant, and (2) experiments where incubation length was held
constant while enzyme concentrations were varied. The first sets of experiments
were used to determine when cells became susceptible to each of the isoforms
and when maximum hydrolysis occurred, while the second set of experiments
determined the maximum hydrolysis for each isoform.

Snake Venom: Addition of sPLA2 to S49 cells incubated in a control vehicle
(DMSO) for 24 h caused a slight increase in ADIFAB GP followed by a gradual
decline, nearly restoring the value to its original level (Fig. 6: Panel A ). Like in
the ionomycin experiments, this unusual hydrolysis time course represents
transient initial hydrolysis, followed by re-acylation of the lipids and
reincorporation into the membrane (12). In contrast, 24 h incubation of cells in
dexametheasone resulted in a large increase in ADIFAB GP that quickly reached
a stable plateau (Fig. 6: Panel A). This sudden increase in ADIFAB GP is not
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nearly as large as that of the ionomycin treatment; however, the increase is still
significant.
Prolonged treatment with DMSO (up to 48 h) had no effect on the kinetics
of membrane hydrolysis by sPLA2 (data know shown). In contrast, cells exposed
previously to dexamethasone for varying lengths of time (6-48 h) displayed an
increase of substrate hydrolysis, as time progressed, reaching a state of
maximum hydrolysis during 18-24 h of treatment. Hydrolysis then decreased at a
moderate rate, to the point where hydrolysis was negligible (Fig. 7: Snake Venom
row). The pooled values for the middle three time points (18,24,30 h) were
distinguishable from zero by t-test (p= 0.0002); the pooled values for the early
and late time points (9,40,48 h) were not significant (p= 0.0562).
In order to compare dexamethasone and ionomycin data, the initial rate
and max hydrolysis of dexamethasone treatment was calculated. This was done
through repeating experiments in Figure 6 with varying concentrations of enzyme
(0.03–1.0 μg/ml). Data in Figure 8 showed an increase of hydrolysis as enzyme
concentration increased (Fig. 8). Values for the maximum hydrolysis rate and
the one-half the maximum were 0.2866 ± 0.01172 GP units s-1, and 0.1135 ±
0.01629 nM respectively. Like the ionomycin experiments, initial hydrolysis in
dexamethasone-treated samples rapidly reached a plateau in lower levels of
enzyme concentrations. Even though the amount of substrate hydrolyzed differs
between the two treatments (ionomycin enhances greater), the EC50 values of
ionomycin- and dexamethasone-treated cells are similar. Control treatment
(DMSO) used for the dexamethasone experiments displayed no significant
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increase of hydrolysis. The results in Figure 8, when compared to the
hypothetical curves in Figure 1, are most similar to the curves in the panel where
step two was limiting. These similarities to the ionomycin experiment and the
step two hypothetical curves reinforce the suggestion that the limiting step for the
snake venom enzyme is step two.

Varied Isoform concentrations with 24 h dexamethasone incubation for
human group isoforms: As was observed with snake venom sPLA2, incubation
of cells with dexamethasone for 24 hrs enhanced the rate of hydrolysis,
compared to control (DMSO) samples for each isoform (Fig. 6). However, the
magnitude of the effect of dexamethasone differed among the isoforms, when
compared to that obtained with ionomycin (Fig. 6). For example, hG-X behaved
similar to the snake venom in that ionomycin was more effective at enhancing the
rate of hydrolysis than was dexamethasone (Fig 6, Panels A and D). In contrast,
the rate of hydrolysis catalyzed by either hG-IIA or hG-V was increased more by
dexamethasone than by ionomycin (Panels B and C).
In order to compare dexamethasone and ionomycin data for each of the
isoforms, the initial rate and max hydrolysis of dexamethasone treatment was
calculated. This was done through repeating experiments in Figure 6 with varying
concentrations of enzyme (0.03–1.0 μg/ml). The Vmax and EC50 values for this
analysis are shown in Table 2. Data from Figure 6 was also compared to the
hypothetical curves from Scheme 1 in Figure 1. This comparison allowed us to
preliminarily concluded that the limiting steps for the hG isoforms. They are as
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follows: hG-X- step two; hG-V – step one; hG-IIA – inconclusive due to lack of
response from ionomycin and DMSO treatments. These results also suggested
that cells which undergo apoptosis are better hydrolyzed by the hGs-IIA and -V
isoforms than cells that undergo necrosis.

Varied Dexamethasone incubation lengths with same enzyme
concentration for human group isoforms: Cells that were incubated for
various lengths of time (6-48hrs) with dexamethasone showed distinct similarities
and differences in hydrolysis kinetics (Figs. 7, 9). Like the snake venom enzyme,
all human group isoforms displayed enhanced hydrolysis for the first 24 h of
dexamethasone incubation. Substrate hydrolysis for the hG-V and -X isoforms
reach a maximum around 24 h dexamethasone treatment, while hG-IIA
maximum hydrolysis is reached at around 18 h (Figs. 7, 9, and 10). This
enhanced hydrolysis with the hG-IIA and -V isoforms only lasts for a short period
time (4-6 hrs, or until after 24-25 h total incubation) before hydrolysis recedes
back to zero (Figs. 7 and 9). Unlike the snake venome, hG-IIA, and -V isoforms,
where hydrolysis returns to base level after prolonged dexamethasone treatment,
hydrolysis by hG-X only slightly decreases (Fig. 9). A one sample t-test was
performed on the dexamethasone data for each of the isoforms. For the hG-IIA
and -V, the test demonstrated that hydrolysis for the middle time points were
significantly different from zero (p = 0.0126, p = 0.0063), while the early and late
time points were not significantly different (p = 0.0718, p =0.8692 respectively).
Results for hG X enzyme showed a significant difference from zero for both sets
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of time points (edge p = 0.0460, middle p = 0.0014). These delayed responses
during apoptosis led us to conclude that there are certain apoptotic events that
occur at these particular stages which increase the rate of hydrolysis.
Moreover, the data in Figure 9 also suggested that the identity of those
events and/or their strength of coupling to hydrolysis might vary among the
isoforms. To better understand the timing relationships among these isoforms,
the number of cells categorized as “alive but susceptible” to hydorlysis by each
isoform were compared. This number was assayed by the initial ability of cells to
exclude propidium iodide, followed by uptake upon addition of enzyme as
explained previously (Fig. 10) (7). This analysis, comparing the population of
cells that are classified as “alive and susceptible” with extended dexamethasone
incubations, showed a correlation between extended incubations and reduced
cells susceptibility (Fig. 10). Figure 10 also displays that the peak activity time
for each of the isoforms is still between 18-24 hrs.
To exclude time as a limiting factor for substrate hydrolysis, experiments
for groups V and IIA were extended to 5000 seconds. Hydrolysis was then
measured as mentioned above. Data illustrated that despite the time extension,
maximum hydrolysis was still considerably less than that of the snake venom and
hG-X isoforms (Data not shown).

DISCUSSION
Theoretical Analysis
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Snake Venom: The model shown in Scheme 1 was used to analyze the results
of the kinetic experiments displayed in Figs. 2 and 8. The initial rate of lipid
catalysis (dP/dt) is given by

eq 1

where β is proportional to kcat and the total number of adsorption sites for the
enzyme (ET) (9). It is assumed that β does not change with experimental
treatment because alterations to membrane structure would presumably affect
reaction steps preceding the catalytic event (9). For simplicity, β is assigned a
value of 1.0 GP units s-1. ST represents the mole fraction of membrane
phospholipids available to the enzyme. In previous analyses, it has not been
considered separately from KE , since the two parameters are completely linked
in the model (see Eq. 1) (9). However, the data of Fig. 3B demonstrate that ST is
subject to change upon experimental treatment and provide information to
quantify the magnitude of that change. ST is therefore included specifically as a
parameter in Eq. 1 and expressed in relative units (i.e. it is assigned a value of
1.0 under control conditions).
As shown in Fig. 11A, the control data from Fig. 3A were well fit by Eq. 1.
The value of KA (6.7 × 107 M-1) matched favorably the value estimated from
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competition with L-PLA2 (2.7 × 107 M-1 in reference iono paper). The effect of
ionomycin on the initial hydrolysis rate was evaluated by considering ST, KA, and
KE individually in the fit, in order to identify the minimum criteria required by the
results (parameter values summarized in Table 1). The data of Fig. 3B indicated
that ST increased by a factor of about 4.4 with ionophore treatment. Accordingly,
Eq. 1 was re-calculated maintaining all parameter values from the fit of the
control data with the exception of ST. The 4.4-fold increase, however, was
insufficient to account for the ionomycin data (Fig. 11B). In fact, a reasonable fit
was obtained only with a much larger (8.1-fold) increase in ST, one that cannot
be justified based on the data of Fig. 3B (Fig. 11C). Since KE and ST are linked in
Eq. 1, the dilemma can obviously be resolved by increasing KE by a factor of 1.8
in addition to a fixed 4.4-fold increase in ST (Fig. 11D). Alternatively, allowing KA
to vary instead of KE was inadequate to accommodate the data (Fig. 11E). The
best fit, of course, was obtained when both KA and KE were allowed to float in
combination with the prescribed increase in ST (Fig. 11F). This ideal fit
corresponded to a 2-fold increase in KE (in strong agreement with that of Panel
D) coupled with a reduction in KA by about 16% (corroborating the result in Panel
E). Thus, we concluded from this analysis that increased susceptibility following
ionomycin treatment has little or nothing to do with the strength of adsorption (KA)
and can be explained entirely by increases in the accessibility of lipids to the
enzyme active site (KE and ST).
The intent of analyzing the two-step model, to the extant that was done
with the ionomycin data, was to allow us to relate the information form the
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arbitrary fits of the isoforms and dexamethasone treatment back to the model,
with simple calculations. The model includes the calculation with equation 1 (21)
and Figure 11 and Table 1. When the second step is a limiting step (and
therefore enhanced by apoptosis), then the expected changes are seen in the
max hydrolysis and not in the Kd for the enzyme. The converse is also true,
when step one is the limiting step that is enhanced by apoptosis, where changes
are expected to be seen between the Kd and not the max hydrolysis. These
examples are illustrated by Figure 3 where the max hydrolysis rate was
distinguishable and the half max was not distinguishable. By using this simple
paradigm, step one and step two can be distinguished in the remaining of the
isoforms, without the technical redundancy that is easily conveyed with one
analysis.
In conclusion results from the ionomycin and dexamethasone experiments
solidify the previous resolution that the limiting step in Scheme 1 for the snake
venom enzyme is step two, or movement of the phospholipid head into the active
site of the enzyme.

Isoforms: The fundamental objective to analyze the kinetic data in the context of
Scheme 1 is to determine what elements of the catalytic mechanism are altered
to produce increased hydrolysis during apoptosis. Specifically, the parameters
assessed in the analysis, determine if cells permit hydrolysis to occur either
because of increased adsorption (step one), or because of easier movement of
phospholipids into the enzyme’s active site (step two). Analysis results from the
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ionomycin section contributed two important observations about the sPLA2
enzyme. First, step one or step two can be distinguished as the limiting step if
either Vmax (step one) or EC50 (step two) changes. Second, the limiting step for
snake venom is clearly step two, regardless whether apoptosis is initiated by
ionomycin or dexamethasone.
Consequently, Scheme 1 was then used to asses the limiting step for
each of the human group isoforms. Based on Figures 5 and 8 and the EC50 and
Vmax explanation above, values of KA and KE (Table 2) can be used to reveal
which step is limiting within the reaction. To was done through calculating a
global analysis of the data in Figure 8, in which each of the two fitting parameters
(KA/EC50 and KE/Vmax) were individually shared (and therefore held constant)
among the data sets, or left to float (Fig. 12). For hG-X enzyme, data in Table 2
and in Figures 8 and 12 suggest that the limiting step in hydrolysis is step two.
This was concluded by the similarity between the three EC50 values (ionomycin,
dexamethasone and DMSO) that were calculated from nonlinear regression
(Table 2), the similarity of those values to that of the EC50 values of the snake
venom enzyme, and by the fact that the hG-X data in Figure 12 were best fit by
varying Vmax. Although, this was not the case with hG-V. When allowing the Vmax
to float while retaining EC50, the global fits were unsatisfactory. However, by
allowing EC50 to float while retaining Vmax, the fits were greatly improved. This
variance suggests the conclusion that enzyme adsorption, and not movement of
the phospholipids into the active site, is the limiting step for the hG-V isoform.
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This conclusion is supported by the fact that hG-V is noted for its affinity to
anionic lipids, namely PS that are exposed during apoptosis (11).
Unlike the hG-X and V data in Figure 12 that clearly illustrates which step
in Scheme 1 is limiting; results from nonlinear regression for the hG-IIA enzyme
are unclear. However, because of the similarity between hG-IIA and hG-V (Fig.
8), we suggest that the limiting step may be step-one. This suggestion is
reinforced by previous studies done by Sang et al. on anionic vesicles that
conclude anionic vesicles increase binding affinity of the hG-IIA enzyme (11).

Negative Charge
It has been previously thought that PS exposure is the sole cause for
increased enzyme binding affinity and hydrolysis for most isoforms (11).
However, data presented in this thesis suggest that PS exposure may not be the
only change in the membrane that increases hydrolysis. This assertion is based
on results showing more anionic lipids are exposed in ionomycin-treated cells
than in cells that have been treated with dexamethasone for 24 h (peak hydrolytic
efficiency) (Figs. 4,6,8). This is because cells are simultaneously induced into
apoptosis during ionomcyin treatments, and thus will have simultaneous PS
exposure of about 100% (7). Whereas, with dexamethasone-treatment, cells do
not progress simultaneously through apoptosis. Thus, PS flip-flop is less
synchronized, and after 24 h, only averages about half the amount of that
observed with ionomycin treatment (7). If PS exposure were indeed the only
significant change in the membrane that enhances substrate hydrolysis, then the
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results for all enzymes should have displayed more substrate hydrolyzed with
ionomycin than with dexamethasone treatment at 24 h. However, since two
enzymes (hG-IIA & hG-V) that are thought to be the most reliant on a negatively
charged membrane (13) show no or very little hydrolysis when treated with
ionomycin (Figs. 4, 5 ), we must conclude that there are other factors, in addition
to PS exposure, that contribute to enhanced hydrolysis.
One of these factors could be oxidation of membrane phospholipids. This
assumption is based on the studies of Fabisiak et al. and Salgo et al. who
concluded that oxidized phospholipids provide a better substrate for sPLA2 than
negative phospholipids for most of the human group isoforms (22, 23). One of
the main activators for phospholipid oxidation is the activation of cytochrome-c
(23). It is also known that during the cascade of events in the dexamethasone
pathway, cytochrome-c is turned on (6). By understanding these activation
factors, the fact that dexamethasone-treated cells are hydrolyzed more
efficiently by hG-IIA and –V is more easily understood.

Membrane Mechanics
Using a glucocorticoid, instead of an ionophore, provided
a more comprehensive understanding of the mechanism by which the sPLA2
enzyme increases hydrolysis in an in vivo environment, and a relative timetable
of maximum cell susceptibility to the enzyme during apoptosis. Cells treated with
dexamethasone and the snake venom enzyme displayed a greater increase in
hydrolysis susceptibility at early stages of apoptosis than with the other isoforms.
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Although the timing of structural changes in the membrane differs between the
two pathways (10) (7), hydrolysis is still significantly increased for both
ionomycin- and dexamethasone-treated cells (Figs. 4, 6, 8). This increased
susceptibility illustrates the ability of the snake venom enzyme to hydrolyze cells
with an amplified catalytic efficiency that is indifferent to the slight variations of
membrane change that correspond with different apoptotic initiators and their
relation to the cell death spectrum.
However, even with the increased catalytic efficiency shown in all
isoforms of the sPLA2 enzyme, the isoforms are still limited by membrane
mechanics. As shown in Figures 7 and 9, the maximum amount of substrate
hydrolysis for all isoforms occurs between 18-24 h incubation with
dexamethasone. This significant increase in hydrolysis during this window of
time correlates with data found in (10) demonstrating that during the same
window, there is also an increase in lipid spacing and membrane hydration. Data
in Figure 9 and 10 also illustrates that the snake venom, hG-IIA and –V enzymes
hydrolyze significantly less substrate as the apoptosis process continues into
later stages. This observation correlates with experiments showing that cell
membranes progress into a more ordered state in the later stages of apoptosis
(10). We therefore think this increase in order is one of the causes for decreased
susceptibility as apoptosis progresses. This result refutes the previous
assumption that dexamethasone-induced apoptosis enhances substrate
hydrolysis by the sPLA2 enzyme as incubation with the glucocorticoid is
prolonged beyond 24h (7). However, this decrease in substrate hydrolysis does
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not pertain to the hG-X enzyme (Fig. 9). The hG-X enzyme has the capacity to
maintain the ability to hydrolyze substrate even while the membrane is highly
ordered; leading us to the conclusion that membrane order is not a controlling
factor in substrate availability.
While the majority of the activity of the enzymes decrease as order
increases in the latter stages of apoptosis, it is unlikely that this latent resistance
to sPLA2 has any physiological significance since cells that are this far along in
the apoptosis pathway would probably have been previously cleared by
macrophages.

Structure and Function
hG-X: The ability of hG-X to hydrolyze highly ordered lipids while none of the
other isoforms share this characteristic, suggested the exploration of the
evolutionary development of the enzyme. According to Cupillard et al. the hG-X
enzyme is the ancestral human group sPLA2 enzyme (24). This conclusion could
explain why the hG-X is still in possession of this trait, and that the other variants
of the sPLA2 enzyme have lost the ability to hydrolyze highly ordered
membranes, when specializing in specific functions.
There are several reasons why the hG-X isozyme behaves most similarly
to the snake venom sPLA2. One of these reasons stems from the fact that the
hG-X isoform can hydrolyze both the zwitterionic and anionic phopholipid with
similar catalytic efficiency (25). Pan et al. attribute this ability to the unique
mixture of disulfide bonds found in the human group X enzyme (15). This
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combination is a compilation of the disulfide bonds found in the structure of both
the human groups I and II enzymes that could have a synergistic effect to
increase hydrolysis (15).
A second reason that possibly accounts for the increased hydrolysis, is
the ability of the enzyme to adsorb to the membrane (25). Ishimoto et al. state
that the hG-X enzyme has a significantly increased rate of hydrolysis and binding
to the phospholipid membrane, compared to hG-IIA and -V (25). Their data
illustrate that the presence of phophatidylcholine increases hG-X hydrolysis of
the membrane, by allowing the enzyme to initially adsorb better to the
phospholipid membrane. Ishimoto et al. state that the reason for the increased
adsorption of hG-X while in the presence of phosphatidylcholine is unknown.
Nevertheless, they theorize that this phenomenon is physiological and suggest
that hG-X has plays a role of relevance in the production of proatherogenic
eicosanoids (25).
Pan et al. suggests a third reason that incorporates the structure of the
enzyme and alternative physical attributes that contribute to hG-X ability to
adsorb to and hydrolyze cellular membranes. According to Pan et al. (2002), one
of the type-X characteristics that are thought to enhance hydrolysis includes a
larger active site that accommodates the functional need to cleave phospholipids
with the sn-2 polyunsaturated chain. Their study also noted that the hG-X
isoform had a three-fold preference for phospholipids with an arachidonic acid
side chain (15). These characteristics (an affinity for sn-2 fatty acids and
interface site that is structured for larger phospholipid) show both the
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evolutionary dexterity of the hG-X enzyme and the hydrolysis dexterity of the
enzyme across the cell death spectrum.

hG-V/hG-IIA: Since the hG-V isoform is thought to be the evolutionary/functional
duplicate of the hG-IIA (11), it is interesting to note the differences between the
two enzymes. One of these differences is the effect of ionomycin on hydrolysis
(Fig. 4). While hG-IIA seems to have no effect on cells that were treated with
ionomycin, cells that were treated with the hG-V enzyme after ionomycin
treatment showed an increased hydrolysis rate and amount as shown in Figures
4 and 5. This increase could be considered small when compared to either the
hG-X or snake venom enzymes; however, it shows is a significant difference
between the hG-IIA and the hG-V isoforms in their selectivity of membrane
characteristics during apoptosis. One possible reason why hG-V has a higher
catalytic activity than the hG-IIA enzyme is its ability to adsorb onto the
membrane. It has been shown that a correlation between sPLA2 isoforms that
are in possession of tryptophans (or other aromatic side chains) on the interfacial
binding surfaces and the enzyme’s ability to hydrolyze cellular membranes (11).
Han et al. then demonstrated that the higher binding affinity in the hG-V enzyme
is attributed to the extra tryptophans that are situated on the putative interfacial
binding surfaces.
In addition to the increased amount of tryptophans possessed by the hG-V
isoform, we hypothesize there may be another, more physiological reason why
substrate hydrolysis by hG-IIA is minimal in lymphoma cells when compared to
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other isoforms. This concept incorporates the theory that the hG-IIA isoform has
become specialized in its function. At some point in the evolutionary time scale,
the hG-IIA isoform exchanged the ability to hydrolyze eukaryotic membranes at
an increased catalytic rate, for the ability to hydrolyze bacterial membranes.
Since bacteria are commonly found within and around the human body, this
niche would be highly beneficial for the enzyme and its host.

CONCLUSION
There are four novel conclusions resulting from the data of this project.
First, negative charge provided by exposed PS at the membrane surface is not
the sole factor determining sPLA2 adsorption/hydrolysis of the phospholipid
membrane. Second, while snake venom, hG-IIA and hG-V isoforms do not
hydrolyze highly ordered phospholipid membranes, the hG-X enzyme does.
Third, all of the isoforms appear to benefit from changes that occur in the
membrane during the early stages of apoptosis. Fourth, the limiting step in
hydrolysis for each of the enzymes is as follows: snake venom- step two; hG-Xstep two; hG-V- step one; and hG-IIA- inconclusive.
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SCHEME 1 Reaction scheme for interaction between sPLA2 and cell
membranes. E, free sPLA2; EB, sPLA2 adsorbed to membrane surface sites
(Ms); S, available substrate (membrane phospholipid); EB s, adsorbed enzyme
with substrate bound to the active site; KA, equilibrium constant for enzyme
adsorption to the membrane; KE, equilibrium constant for substrate migration into
the enzyme active site; kcat, turnover number for substrate hydrolysis; P, product
(fatty acid).
FIGURE 1: Hypothetical curves for the analysis of Scheme 1. Panel A
displays if adsorption, step-one, was the limiting step. EC50 was left to float while
Vmax was held constant. Panel B displays if the phospholipids movement into the
active site, step-two, is the limiting step. Vmax was allowed to float while EC50
was held constant. In each panel the red curve represents ionomycin/
dexamethasone treatment and the blue curve represents the control/DMSO
treatment.
FIGURE 2: Effects of ionomycin treatment on the time course of membrane
hydrolysis by sPLA2. S49 cells were incubated with ADIFAB and treated for at
least 600 s with DMSO (curve a) or ionomycin (curve b) as explained in Materials
and Methods. At the time indicated by the arrows, sPLA2 (70 nM final) was
added. Data points represent the raw data (expressed in GP units), and curves
represent nonlinear regression fits of the data using an arbitrary function
consisting of the sum of two exponential functions. The amount of hydrolysis
observed in curve b constitutes approximately 2–5% of the plasma membrane
phospholipid (1).
FIGURE 3: Secretory PLA2 concentration dependence of the initial rate of
hydrolysis. Panel A: the experiments of Fig. 1 were repeated at the indicated
concentrations of sPLA2 for cells treated with DMSO (squares) or ionomycin
(triangles). The initial rate was defined as the amount of product generated
during 5 s from the time of enzyme addition. This number was calculated from
nonlinear regression fits of the data as shown in Fig. 1. Data were analyzed by
two-way analysis of variance to assess the contribution of sPLA2 concentration
(37% of variation, p < 0.0001), ionomycin treatment (13% of variation, p <
0.0001), and the interaction between the two (20% of variation, p < 0.0001).
Data points represent the raw data (expressed in GP units), and curves
represent nonlinear regression fits of the data using an arbitrary function. Panel
B: the total amount of product after 600 s (or at the maximum for time courses
shaped like that of curve a in Fig. 1) for enzyme concentrations ≥18 nM. The data
were significant based on two-tailed unpaired Student’s t test (p < 0.0001, n = 1–
4 at each datum).
FIGURE 4: Ionomycin treatment has varying effects on sPLA2 isoforms.
S49 cells were incubated with ADIFAB and treated for at least 700 s with DMSO
(blue curve) or ionomycin (red curve) as explained in Materials and Methods. At
around 700 s, sPLA2 (35 nM final) was added. Panel A: addition of snake venom
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enzyme; Panel B: addition off hG-IIA enzyme; Panel C: addition of hG-V enzyme;
Panel D: addition of hG-X enzyme. Curves are raw data represented by ADIFAB
GP.
FIGURE 5: Ionomycin treatment increases the amount and initial rate of
membrane hydrolysis by sPLA2: Experiments of Figure 4 were repeated at the
indicated concentrations of sPLA2 isoforms for cells treated with DMSO (squares)
or ionomycin (circles). The initial rate was defined as the amount of product
generated during time indicated in panel from the time of enzyme addition. Initial
rates were calculated at 10s for snake venom, 300s for hG IIA, and 100s for hG
V and hG X. This number was calculated from nonlinear regression fits of the
data as shown in Figures 1 and 4 (data not shown).
FIGURE 6: Dexamethasone causes increased activity for all isoforms. Cells
were treated with dexamethasone (black) or DMSO (blue) for 24 h prior to
enzyme addition (~750 s). At around 700 s, sPLA2 (35 nM final) was added.
Panel A: addition of snake venom enzyme; Panel B: addition off hG-IIA enzyme;
Panel C: addition of hG-V enzyme; Panel D: addition of hG-X enzyme. Curves
are raw data represented by ADIFAB GP.
FIGURE 7: Effect of dexamethasone incubation time on membrane
hydrolysis by sPLA2 isoforms. S49 cells were incubated with dexamethasone
for varying lengths of time (6-48 hrs). At 100 s samples were treated with
ADIFAB and left to incubate for 600 s as explained in Materials and Methods. At
the time 750 s sPLA2 (70 nM final) was added. Curves are raw data represented
by ADIFAB GP.
FIGURE 8: Dexamethasone treatment increases initial hydrolysis by all
isoforms: Experiments of Figure 6 were repeated at the indicated concentrations
of sPLA2 isoforms for cells treated with DMSO (squares),ionomycin (triangles), or
dexamethasone (circle). The initial rate was defined as the amount of product
generated during time indicated in panel from the time of enzyme addition. Initial
rates were calculated at 10s for snake venom, 300s for hG IIA, and 100s for hG
V and hG X. This number was calculated from nonlinear regression fits of the
data as shown in Figures 3 and 5. Ionomycin and DMSO data taken from Figure
6. Nonlinear regression fits of the data calculated the apparent dissociation
constants represented in the table below.
FIGURE 9: Summary of hydrolysis experiments by sPLA2 isoforms. A
comparison of hydrolysis by sPLA2 isoforms when cells are treated with
dexamethasone. One sample t-test was performed on each of the isoforms,
dividing the data into two groups. Group a consisting of the outside, or early and
late, time points, and group b consisted of the middle three time points. For the
snake venom, hG IIA and V there was a significant difference between the
middle time points and zero but not the outside time points. For the hG-X
enzyme both sets of data points were significantly different from zero.
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FIGURE 10: Percent of cells that are categorized as Alive and Susceptible
from propidium Iodide data graphed against time. S49 cells that have been
treated with dexamethasone for varying lengths of time (6-48 h) show a decrease
in cells that are susceptible to the enzyme as incubation time increases. Data
points represent the average of cells that are categorized as cells that are alive
and susceptible, and the error bars represent the standard error of the mean.
FIGURE 11: Analysis of hydrolysis results in terms of Scheme 1. Initial
sPLA2 hydrolysis rates from Fig. 2A were fit by nonlinear regression to Eq. 1
multiple times with various combinations of constraints. Panel A: baseline
parameter values were obtained by fitting the control (DMSO) data from Fig. 2A;
parameter values are listed in the first row of Table 1. Some parameters were
allowed to float in fits of the ionomycin data (Panels B–F) as detailed below. ST
was fixed at 1.0 GP units in Panel A and at 4.66 GP units with the ionomycin
data (except in Panel C) as explained in the text. The remaining parameters
were kept fixed at the values obtained in Panel A (details in rows 2–6 of Table 1).
The parameters allowed to float during the fits for each panel were: Panel B:
none, Panel C: ST, Panel D: KE, Panel E: KA, Panel F: KE and KA.
FIGURE 12: Analysis of hydrolysis results in terms of Scheme 1 for sPLA2
isoforms. Initial sPLA2 hydrolysis rates from Fig. 8 Panels C (hGV) and D (hG X)
were fit by nonlinear regression to Eq. 1 multiple times with various combinations
of constraints. Some parameters were allowed to float in fits of the ionomycin,
DMSO and dexamethasone data (Black = dex, Blue = DMSO, Red = ionomcyin)
as detailed below. Panel A: baseline parameter values were obtained by fitting
the control (DMSO) data from Fig. 8C (Blue solid, doted and dashed lines). The
parameters allowed to float during the fits for each treatment were: Dashed line:
none, Solid line: KE (shared max), Dotted line: KA (Shared Kd).

37

TABLE 1 Parameter values for Fig. 11.
Parameters
Fig. 11 Panel

β
(GP units s-1)

KA
(nM-1)

KE

ST
(relative

A

1.0

0.067

0.10

1.0

B

1.0

0.067

0.10

4.43

C

1.0

0.067

0.10

8.12

D

1.0

0.067

0.18

4.43

E

1.0

0.273

0.10

4.43

F

1.0

0.056

0.20

4.43

Parameter values were obtained by nonlinear regression using Eq. 2 as
explained in the legend to Fig. 11. Values allowed to float in the regression are
underscored
.
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TABLE 2 Parameter values for Fig. 8
Table 3

Treatment

Parameters
-1

hG-IIA

hG-V

hG-X

2.7 ± 1.5

0.22 ± 0.08

0.15 ± 0.02

0.62 ± 0.23

0.24 ± 0.03

0.52 ± 0.02

Dex

EC50 nM

Dex

Vmax GP units s-

Ionomyci

EC50 nM-1

N/A

1.10 ± 0.97

0.12 ± 0.07

Ionomyci

Vmax GP units s-

N/A

0.28 ± 0.15

0.67 ± 0.12

DMSO

EC50 nM-1

N/A

1.3 ± 1.2

0.39 ± 0.54

DMSO

Vmax GP units s-

N/A

0.18 ± 0.10

0.31 ± 0.17

Parameter values were obtained by nonlinear regression using Eq. 1 as
explained in the legend to Fig. 8.
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